Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis / 대한내과학회지
Korean Journal of Medicine
;
: 229-232, 2015.
Article
in Korean
| WPRIM
| ID: wpr-102977
ABSTRACT
Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to treat hyperuricemia and gout, but it is necessary to adjust the dosage according to the degree of renal impairment. Uncommonly, allopurinol may have severe or fatal side effects. The non-purine xanthine oxidase inhibitor febuxostat undergoes hepatic metabolism and may require less dose adjustment in association with renal function. It is considered to be an alternative treatment for hyperuricemic patients with chronic kidney disease. Our experience suggests that low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Uric Acid
/
Xanthine Oxidase
/
Arthritis, Gouty
/
Allopurinol
/
Peritoneal Dialysis
/
Peritoneal Dialysis, Continuous Ambulatory
/
Hyperuricemia
/
Renal Insufficiency, Chronic
/
Febuxostat
/
Gout
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS